A new study to be presented at the 2017 Genitourinary Cancers Symposium has found that some patients with advanced renal cell carcinoma had a durable response after treatment discontinuation.
A new study to be presented at the 2017 Genitourinary Cancers Symposium has found that 42% of patients with advanced renal cell carcinoma (RCC) had a durable response even after they had discontinued treatment early due to side effects.
The programmed death 1 (PD-1) inhibitor nivolumab (Opdivo), has been found to improve survival in patients with metastatic RCC (mRCC), and is administered on a continuous basis until disease progression or toxicity. For the study, the authors continued to follow patients who had stopped treatment with a PD-1/ programmed death ligand-1 (PD-L1) inhibitor due to immune-related adverse events (irAEs).
Of the 19 patients with mRCC who had responded to immune checkpoint inhibitor treatment, 62% had received a PD-1/PD-L1 inhibitor alone and 37% received PD-1/PD-L1 inhibitors in combination with other systemic treatments. Nine patients who responded to a PD-1/PD-L1 inhibitor discontinued treatment because of an irAE—7 of the 9 were treatment naïve. The irAEs reported were joint pain; eye problems; pituitary gland, muscle, heart, liver, pancreas, kidney, or lung inflammation; and diarrhea. Four of the 9 patients (44%) received PD-1/PD-L1 monotherapy for a median duration of 5.5 months (range 4 to 15 months).
Four patients (44%) whose median time on therapy was 9 months (range 4 to 15 months), remained progression free at 20 months (range 10 to 44 months) after they stopped treatment with their PD-1/PD-L1 inhibitor. For the 5 patients (56%) who progressed within 6 months (range 2 to 6 months) of treatment discontinuation, median time on therapy was 4 months (range 3 to 10 months).
Considering the small sample size of the study, additional studies with a larger cohort of patients is definitely warranted. However, the study findings are novel and point to the lasting duration of impact of checkpoint inhibitors. Future studies could be designed to understand the molecular pathogenesis of a durable response in these patients.
“This study is welcome news for patients who are unable to continue immunotherapy as a result of adverse effects,” said Sumanta Pal, MD, who moderated a presscast by the American Society of Clinical Oncology, which is hosting the meeting. “It’s very reassuring to see that some patients may continue to benefit from immunotherapy even if they need to discontinue it. More broadly, these findings call into question the current standard of continuous treatment with immunotherapy, though longer term follow-up of patients is needed.”
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More